Insights
Search Results
Client Highlights
10.12.26
Wilson Sonsini Advises Armada Acquisition Corp. II on Business Combination with Evernorth Holdings
On October 9, 2026, Armada Acquisition Corp. II (Armada II), a special purpose acquisition company, and Evernorth Holdings (Evernorth), a digital asset treasury company building institutional access to the XRP economy, announced the completion of their business combination. Evernorth’s common stock is expected to begin trading on the Nasdaq Stock Market on October 12, 2026, under the ticker symbol “XRPN.” Investors included Arrington Capital, SBI Group, Ripple, Pantera Capital, Kraken, and GSR, among others.
Client Highlights
10.01.26
Wilson Sonsini Advises Stripe on Acquisition of Parafin
On September 30, 2026, Stripe, the programmable financial services company, announced that it has agreed to acquire Parafin, a leading embedded financial products platform. Wilson Sonsini Goodrich & Rosati is advising Stripe on the transaction.
Client Highlights
9.29.26
Wilson Sonsini Advises World Labs on $8.2 Billion Acquisition by AMD
On September 28, 2026, AMD, a global semiconductor company, announced it has entered into a definitive agreement to acquire World Labs, an AI model and research lab led by AI pioneer Dr. Fei-Fei Li. The acquisition will bring a world-class team of researchers and model experts to AMD, strengthening its ability to develop AI hardware, software, and systems. Wilson Sonsini Goodrich & Rosati is advising World Labs on the transaction.
Client Highlights
9.21.26
Firm Advises CoVet on Acquisition by IDEXX
On September 16, 2026, IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announced the acquisition of CoVetAI Inc. (CoVet), a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. The financial terms of the transaction were not disclosed. Wilson Sonsini Goodrich & Rosati advised CoVet on the transaction.
CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing documentation burden and saving clinicians’ time. The acquisition expands the value of IDEXX’s software, diagnostics, and AI offerings by making information more accessible, actionable, and connected across the practice. CoVet will be integrated into the IDEXX software ecosystem, which will continue to support other ambient scribe solutions and third-party integrations. CoVet will also continue to integrate with non-IDEXX practice management systems.
The Wilson Sonsini team that advised CoVet on the transaction included:
CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing documentation burden and saving clinicians’ time. The acquisition expands the value of IDEXX’s software, diagnostics, and AI offerings by making information more accessible, actionable, and connected across the practice. CoVet will be integrated into the IDEXX software ecosystem, which will continue to support other ambient scribe solutions and third-party integrations. CoVet will also continue to integrate with non-IDEXX practice management systems.
The Wilson Sonsini team that advised CoVet on the transaction included:
Client Highlights
7.30.26
Firm Advises Secturion Systems on Acquisition by Carlyle Group
On July 27, 2026, global investment firm Carlyle announced that it had acquired Secturion Systems, a leading provider of high-speed, NSA-certified hardware encryption solutions that protect sensitive and classified information. The transaction marks the first investment by Carlyle’s dedicated middle-market Aerospace, Defense & Government, and Industrials platform. Wilson Sonsini Goodrich & Rosati advised Secturion on the transaction.
Client Highlights
7.09.26
Wilson Sonsini Advises Beam Benefits on Acquisition by Principal Financial Group
On July 7, 2026, Principal Financial Group announced an agreement to acquire Beam Benefits, an employee benefits company serving more than 25,000 small businesses. Principal currently serves 180,000 employers, providing comprehensive retirement, benefits, and business owner solutions. The acquisition is expected to close in the latter half of 2026, subject to the completion of customary closing conditions and regulatory approvals. Wilson Sonsini Goodrich & Rosati advised Beam Benefits on the transaction.
Client Highlights
6.02.26
Wilson Sonsini Advises Contentful on Acquisition by Salesforce
On June 1, 2026, Salesforce, the world's No. 1 AI CRM, announced that it has signed a definitive agreement to acquire Contentful, a leading composable content platform trusted by over 4,800 of the world’s leading brands to deliver personalized digital experiences at scale. Wilson Sonsini Goodrich & Rosati advised Contentful on the transaction.
Client Highlights
4.29.26
Firm Advises Match Group on $100 Million Investment in Sniffies
On April 27, 2026, Match Group, a leading provider of digital technologies designed to help people make meaningful connections, announced a $100 million investment in Sniffies, a map-based platform serving non-heterosexual men. The investment represents a significant minority ownership stake and includes the option to acquire the remaining equity in the future. Sniffies will continue to operate independently and remain founder-led, with Match Group supporting the team's vision and growth. Wilson Sonsini Goodrich & Rosati advised Match Group on the transaction.
Client Highlights
4.14.26
Firm Advises Getlabs on Acquisition by Function
On April 8, 2026, Function Health announced it has acquired Getlabs, a leading mobile healthcare platform that brings licensed specialists directly to one's location. The acquisition allows for the continuation of Getlab’s nationwide network of providers, health systems, and partners, while advancing Function's broader commitment to making healthcare more accessible by building experiences around member needs. Wilson Sonsini Goodrich & Rosati advised Getlabs on the transaction.
Client Highlights
4.06.26
Wilson Sonsini Advises Soleno Therapeutics on $2.9 Billion Acquisition by Neurocrine
On April 6, 2026, Neurocrine Biosciences and Soleno Therapeutics announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.